Embracing the transformational potential of new molecular profiling and artificial-intelligence-based data processing technologies on clinical and scientific innovation, Weill Cornell Medicine has created a new research department, the Department of Systems and Computational Biomedicine. Dr.
Meet 2026 Summer Intern Salah!
September 23, 2026
We hope you enjoy learning about our 2026 EIPM summer intern Salah, who worked under EIPM Member Alexandros Sigaras MS, Assistant Professor of Research in Physiology and Biophysics, in our AI-XR Lab! Here he explains how his summer project developed, the technical skills he learned, challenges he overcame, fun he had, and how his confidence grew over time!
Applications for our summer 2027 internship will open in a few months: https://eipm.weill.cornell.edu/education/students
Why Read a Research Paper When You Can Turn It Into an AI Agent?
September 23, 2026
Why Read a Research Paper When You Can Turn It Into an AI Agent?
Smart-Start Therapy for Canine B-Cell Lymphoma
September 16, 2026
Lymphoma is one of the most common cancers we see in dogs. The current standard treatment — a combination chemotherapy protocol called CHOP — has been used for decades and can put most dogs into remission. Unfortunately, the cancer usually comes back within 6 to 12 months, and once it returns, it becomes much harder to treat.
We also know that CHOP has real drawbacks for families and their dogs: It's a big commitment. Treatment represents a significant financial investment and requires frequent visits to the veterinary hospital over several months.
A Conversation with Eleni Andreopoulou, M.D.
September 2, 2026
Q: What first drew you to medicine, and later to breast oncology?
Dr. Andreopoulou:
I was drawn to medicine from an early age by both intellectual curiosity and a desire to care for others. I grew up in a family that deeply valued education and service, and those values, combined with my love of biology, chemistry, and pharmacology, naturally led me toward medicine.
September 2026 EIPM Director's Memo
September 1, 2026
Dear Friends & Members of the Englander Institute,
Model Helps Scientists Build Better Protein-Degrading Therapies
August 31, 2026
A team of Weill Cornell Medicine investigators has developed a computer model that will help scientists more efficiently develop protein-destroying therapies, a newer type of treatment that is particularly promising for cancer. The studywas published July 13 in Nature Communications.
Radiopharmaceutical May Benefit Patients with Metastatic Prostate Cancer Sooner
August 7, 2026
Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.
Mapping Human Bone Marrow Yields New Tool, Insights on Blood Cancer
July 21, 2026
Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.